Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study
Open Access
- 30 April 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 20 (5), 728-740
- https://doi.org/10.1016/S1470-2045(19)30098-1
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaThe New England Journal of Medicine, 2014
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaThe New England Journal of Medicine, 2014
- Semiautomated Volumetric Measurement on Postcontrast MR Imaging for Analysis of Recurrent and Residual Disease in Glioblastoma MultiformeAmerican Journal of Neuroradiology, 2013
- Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyNeuro-Oncology, 2013
- Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid TumorsClinical Cancer Research, 2013
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomasThe Lancet Oncology, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Statistical methods for the assessment of prognostic biomarkers (Part I): DiscriminationNephrology Dialysis Transplantation, 2010
- Response criteria for gliomaNature Clinical Practice Oncology, 2008
- User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliabilityNeuroImage, 2006